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ABSTRACT
Background. The objective of CaLIPSO, a Phase 2b, randomized, double-blind, placebo-controlled clinical trial, is to test
the hypothesis that myo-inositol hexaphosphate (SNF472) attenuates the progression of cardiovascular calcification
in patients receiving maintenance haemodialysis. Here we report the trial design and baseline characteristics of trial
participants.
Methods. Adult patients on maintenance haemodialysis (6 months) with an Agatston coronary artery calcium score,
as measured by a multidetector computed tomography scanner, of 100–3500 U were enrolled. Patients were stratified by
Agatston score (100–<400, 400–1000 or >1000 U) and randomized in a 1:1:1 ratio to receive placebo, SNF472 300 mg or SNF472
600 mg administered intravenously three times weekly during each haemodialysis session.
Results. Overall, 274 patients were randomized. The mean age of trial participants was 63.6 (standard deviation 8.9) years
and 39% were women. The coronary artery, aorta and aortic valve median (25th-75th percentile) Agatston scores at baseline
were 730 U (315–1435), 1728 U (625–4978) and 103 U (31–262), respectively, and the median (25th–75th percentile) calcium
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volume scores at baseline were 666 (310–1234), 1418 (536–4052) and 107 (38–278), respectively. Older age and diabetes mellitus
were associated with higher calcium scores at baseline.
Conclusions. The CaLIPSO trial enrolled patients on haemodialysis with pre-existent cardiovascular calcification to test the
hypothesis that SNF472 attenuates its progression in the coronary arteries, aorta and aortic valve.
Keywords: chronic kidney disease, coronary artery calcification, randomized clinical trial, SNF472, vascular calcification
INTRODUCTION
Chronic kidney disease (CKD) is associated with significant mor-
bidity, premature mortality, reduced quality of life and high
health care expenditures [1, 2]. Traditional risk factors for the de-
velopment and progression of CKD include advanced age, cardio-
vascular disease, diabetes mellitus, hypertension and obesity [3].
As kidney function declines, a variety of metabolic and hormonal
changes occur, many of which result in disordered mineral
metabolism, existing within a state of chronic inflammation and
multiple organ dysfunction [4–8]. Disorders of mineral metabo-
lism in CKD include phosphate retention and elevated serum
concentrations of phosphaturic hormones, including parathyroid
hormone (PTH) and fibroblast growth factor 23 (FGF23). A large
body of evidence indicates that soft tissue calcifications,
particularly cardiovascular calcification, contribute to cardiovas-
cular morbidity and mortality in patients with CKD [9, 10].
Cardiovascular calcification is an actively regulated process con-
trolled by multiple cellular and humoral mechanisms, including
the loss of inhibitors of mineralization typically expressed by vas-
cular cells and the overexpression of osteogenic processes oper-
ating within vascular lesions, including those that promote
hydroxyapatite nucleation and crystal growth [4].
The reported prevalence of coronary artery calcification (CAC)
increases from 40% in patients with moderate to advanced
(Stage 3/4) CKD [11–13] to 60% in patients at haemodialysis initi-
ation and up to 80% in patients receiving maintenance haemo-
dialysis [14]. Cardiovascular calcification may be a modifiable
phenomenon [15]. Thus management guidelines for CKD mineral
and bone disorder (CKD-MBD) recommend the diagnosis and
management of cardiovascular calcification in all patients with
at least moderately decreased kidney function (Stage 3a or higher
CKD) [16]. In these patients, computed tomography (CT) may be
used to determine the presence or absence of cardiovascular cal-
cification; lateral abdominal radiograph for vascular calcification
and echocardiogram for valvular calcification are reasonable
alternatives [16]. Recommended management strategies to re-
duce cardiovascular calcification include lowering elevated se-
rum phosphate while avoiding calcium-based phosphate binders
to prevent net positive calcium balance [16].
Several large, randomized clinical trials in patients receiving
dialysis have evaluated a number of therapeutic interventions
to reduce cardiovascular events, but they required large sample
sizes [17–20]. These and other studies did not show a cardiovas-
cular benefit; thus a significant unmet need remains.
SNF472 is an intravenous formulation of the hexasodium
salt of myo-inositol hexaphosphate (IP6, phytate), a compound
that targets vascular calcification by binding to the growth sites
of the hydroxyapatite crystal and inhibiting hydroxyapatite nu-
cleation and crystal growth [21, 22]. IP6 is a naturally occurring
substance found in beans, brown rice, corn, sesame seeds,
wheat bran and other high-fibre foods; however, oral absorption
is low. IP6 is normally present in minimal concentrations (in the
micromolar range) in body fluids [21, 22].
CaLIPSO is a Phase 2b, multicentre, randomized, double-blind,
placebo-controlled clinical trial testing the hypothesis that SNF472
compared with placebo attenuates the progression of cardiovascu-
lar calcification in patients receiving maintenance haemodialysis.
In this report we present the design of the CaLIPSO trial and sum-
marize baseline characteristics of the trial participants.
MATERIALS AND METHODS
Trial participants
Adult men and women (18–80 years) receiving haemodialysis
for 6 months were screened for eligibility. Initially the trial
recruited patients with an Agatston CAC score between 100 and
2000 U measured by a multidetector CT scanner (MDCT). An
amendment to the protocol increased the upper limit to 3500 U,
which is more fully representative (and inclusive) of this com-
plex patient population (Table 1). Ethical approval was obtained
in accordance with the local/national processes for each study
site. All participants provided written informed consent prior to
enrolment. The trial, which was conducted according to the
principles of the Declaration of Helsinki, was registered at
EudraCT (2016-002834-59) and ClinicalTrials.gov (NCT02966028).
Overview of trial design
CaLIPSO consisted of three different phases: screening for
28 6 3 days, double-blind treatment for 52 weeks and safety as-
sessment 4 weeks after administration of the last dose of study
drug (Figure 1). Patients who met eligibility criteria were ran-
domized on Day 1 in a 1:1:1 ratio to receive placebo, SNF472 300
mg or SNF472 600 mg, three times weekly during haemodialysis
sessions. In view of the overall association of Agatston CAC
score with progression of cardiovascular calcification, randomi-
zation was stratified by baseline Agatston CAC score, divided
into three categories: 100–<400, 400–1000 and >1000 U.
Study visits in CaLIPSO were scheduled for screening, base-
line (Week 1) and Weeks 2, 4, 6, 10, 16, 22, 28, 34, 40, 46, 52 (last
dose) and 56. If the patient terminated study treatment earlier
than planned, then the assessments scheduled for the Week 52
visit were conducted at an early termination visit.
At screening and Week 52, imaging of the coronary arteries,
aorta and aortic valve was performed using MDCT, with a mini-
mum of 64 slices. Contiguous 3 mm tomographic slices from
above the aortic arch to the diaphragm were obtained at end-
expiration and reconstructed during diastole or at the time of least
motion. All scans were centrally reviewed and each calcified area
was quantified using both volume [23] and Agatston score [24].
The Agatston score is more sensitive to the calcium content of a
plaque, but it is less reproducible than the volume score [25], thus
the calcium volume score was selected as the primary endpoint.
Total hip and femoral neck bone mineral density (BMD) were
measured at screening and Week 52 by dual-energy X-ray ab-
sorptiometry. Imaging modality, anatomical positioning,
Trial design and baseline characteristics of CaLIPSO | 367
coverage and parameter were consistent across both imaging
visits for each patient. The left femur was scanned at both vis-
its; if a fracture, prosthesis, deformity or problem prohibited
scanning of the left femur, then the right femur was scanned at
both visits. A foot positioner was used to keep the femoral shaft
straight and parallel to the edge of the scanned image, with the
greater trochanter centred vertically in the window. The entire
femoral head was visible, with a 25 internal rotation of the hip
showing minimal or no lesser trochanter on the scanned image.
For the Hologic scanner (Marlborough, MA, USA), the array
mode was used for each image, while for the Prodigy Lunar
scanner (GE Healthcare, Chicago, IL, USA) automatically chose
thin (<13 cm), standard (13–25 cm) or thick (>25 cm) depending
on the body thickness and height/weight of the patient.
Samples for pharmacokinetic and biomarker analyses were
collected from a subset of participants at selected sites before
Table 1. Trial eligibility criteria
Inclusion criteria
Female or male patients
CAC score of 100–3500 U inclusive within a 4-week period prior to randomization, as measured by an MDCT scanner
Patients 18–54 years of age at randomization with a history of diabetes mellitus or 55–80 years of age at randomization (with or without a his-
tory of diabetes mellitus)
Patients receiving haemodialysis for 6 months prior to randomization
Exclusion criteria
Scheduled date for kidney transplant from a known living donor
Weight >300 lb (136 kg)
Hospitalization in the previous 3 months prior to randomization for unstable angina, myocardial infarction, stroke, transient ischeamic at-
tack, amputation or peripheral or coronary bypass surgery
History of unstable heart failure in the previous 3 months, defined as an unplanned presentation to a hospital or dialysis treatment facility
with signs/symptoms of acute pulmonary oedema and requiring ultrafiltration therapy
History of cancer that has been in remission for <5 years prior to randomization. A history of basal cell carcinoma or Stage 1 squamous cell
carcinoma of the skin is allowed
Pregnant or trying to become pregnant, currently breastfeeding or of childbearing potential (including perimenopausal women who have
had a menstrual period within 1 year) and not willing to practice birth control using a double-barrier method (criteria apply to women only)
at least 30 days after the last dose of study medication
Hypocalcaemia, defined as serum calcium <8.0 mg/dL (or 2.0 mmol/L) for the serum calcium most proximal to screening per patient’s medi-
cal records
Extreme elevation in serum phosphorous, defined as phosphorous >10 mg/dL (or 3.23 mmol/L) within the last 2 months proximal to screen-
ing per patient’s medical records
Uncontrolled hypertension, defined as any two or more consecutive post-dialysis diastolic blood pressure measurements >100 mmHg within
the last 2 months proximal to screening
Expected survival <2 years in the investigator’s medical opinion
Known active drug or alcohol abuse within 1 year of randomization
Use of other investigational drugs within 30 days of randomization
Non-compliance with dialysis treatment that, in the opinion of the investigator, as evidenced by either repeated missed dialysis treatments
or significant non-compliance with the patient’s medication regimen
Inability to comply with all required study procedures and schedules, inability to speak and read in the protocol-derived language of that
patient’s clinical site or unwillingness or inability to give written informed consent
FIGURE 1: CaLIPSO trial flow chart. In Step 1, potential study participants who satisfied the inclusion and exclusion criteria underwent an assessment by MDCT scanner
to determine the Agatston score for the coronary artery, as well as dual-energy X-ray absorptiometry for BMD of the total hip and femoral neck. Patients with con-
firmed calcification of the coronary artery (initially 100–2000 U; later 100–3500 U) at Step 1 entered Step 2 to complete all other screening assessments and confirm all el-
igibility criteria were met.
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and after the infusion of SNF472/placebo at baseline and Weeks
10, 22 and 52. Laboratory analyses, including haematology, co-
agulation and chemistry, were performed at baseline and
Weeks 10, 28, 40 and 52 via a central laboratory.
A Data and Safety Monitoring Board (DSMB) was formed to
monitor patient safety and data integrity during the study. In
January 2019, a futility analysis was performed based on data
from the first 136 patients and the DSMB recommended contin-
uation of the study.
Statistical analysis
In this report we describe baseline characteristics of patients
enrolled in the study, including demographics, medical history,
current and prior medications and calcium scores (Agatston
and calcium volume). We calculated the Spearman’s correlation
between the Agatston CAC score and CAC calcium volume score
at baseline. We used an exploratory multiple linear regression
model to identify associations with the log-transformed CAC vol-
ume score at baseline. Based on prior research [26], candidate
variables in the initial model were sex (male/female), age (years),
dialysis vintage (months), PTH, magnesium, diabetes (yes/no),
non-calcium-based phosphate-binder use (yes/no), statin use
(yes/no), warfarin use (yes/no) and history of overt atheroscle-
rotic cardiovascular disease (yes/no). Stepwise regression was
used to identify factors associated with baseline log-transformed
CAC volume score with 0.10 significance level for entry into the
model and 0.10 significance level for remaining in the model.
Analyses were conducted using SAS version 9.3 or above (SAS
Institute, Cary, NC, USA). Results for body mass index were not
included in this baseline analysis.
The primary endpoint of the study will be the change in log cor-
onary artery calcium volume score from baseline to Week 52 for
the combined dose groups versus placebo. Secondary endpoints
are change from baseline in log Agatston CAC score at Week 52;
proportion of patients with <15% progression in Agatston CAC
score at Week 52; change in thoracic aorta calcium score from
baseline to Week 52; change in aortic valve calcium score from
baseline to Week 52; incidence of composite safety endpoint that
includes death from cardiovascular causes, myocardial infarction,
stroke or heart failure; mortality rate (all-cause and cardiovascular);
change from baseline in levels of selected biomarkers including C-
reactive protein, fetuin-A, FGF23, matrix gla protein (MGP), sclero-
stin and growth differentiation factor 15; change in BMD between
baseline and 52 weeks and safety. Exploratory endpoints include
change from baseline in pulse pressure, systolic blood pressure
and diastolic blood pressure at Weeks 28 and 52 in all patients.
The modified intention-to-treat analysis population is used
for all primary and secondary efficacy analyses. This population
consists of all randomized patients who receive at least one
dose of SNF472 or placebo and have at least one post-
randomization evaluable CT scan with a CAC score. The safety
population will include all randomized patients who receive at
least one dose of SNF472 or placebo. The CAC volume score is
log-transformed prior to analysis. The primary analysis model
is an analysis of covariance (ANCOVA) with the change in log
score (log[Week 52] – log[baseline]) as the dependent variable,
and a fixed effects term for the randomized treatment group as
well as log(baseline) as a covariate; the model is stratified by
baseline Agatston CAC score. For secondary efficacy outcomes,
ANCOVA is used to compare combined SNF472 doses versus
placebo and SNF472 300- and 600-mg doses versus placebo indi-
vidually. For the event-driven secondary outcomes, Kaplan–
Meier product limit estimates are used to display the data and
proportional hazards (Cox) regression is used to compare
SNF472 to placebo, stratified by baseline Agatston CAC score.
The planned sample size for CaLIPSO was approximately 270
patients. Based on available data [26], assuming a standard de-
viation (SD) of the mean change in CAC volume score of 0.30 on
the log scale (from baseline to Week 52) and a dropout rate of
25%, the sample size (i.e. 90 patients per group) was selected to
provide 80% power to test the hypothesis that the log-
transformed true difference in progression between the com-
bined SNF472 doses and the placebo group is 0.126, correspond-
ing to a true ratio of 1.134, or 19% progression for the average of
the SNF472 doses and 35% progression for the placebo group.
RESULTS
Enrolment
Of 645 patients from 72 centres who were screened for enrol-
ment, 239 did not meet the inclusion criteria, most of whom
(n¼ 231) did not have an Agatston CAC score within the re-
quired range at screening. Other reasons for not entering the
randomization are shown in Table 2. A total of 274 patients
were randomized to one of the three treatment groups. Of these,
82 (30%) had an Agatston CAC score of 100–399 U, 77 (28%) had a
score of 400–1000 U and 115 (42%) had a score >1000 U.
Demographics and clinical and laboratory
characteristics at baseline
The mean age of the 274 randomized patients was 63.6 years
(SD 8.9) and 39% were women (Table 3). Demographic character-
istics and vital signs were similar across the Agatston CAC score
strata. Most patients (93%) had hypertension, 62% had diabetes
mellitus, 22% had clinical history of coronary artery disease and
16% had congestive heart failure. Patients with higher Agatston
CAC scores had a numerically higher prevalence of diabetes
mellitus, coronary artery disease and congestive heart failure
than those with lower Agatston CAC scores. The median dura-
tion of haemodialysis was 42.4 months.
Laboratory parameters were generally similar across the
Agatston CAC score strata (Table 4). In each treatment group,
serum PTH was well above the normal range (10–65 pg/mL) and
magnesium was slightly above the normal range (1.7–2.2 mg/
dL). However, serum PTH concentrations were consistent with
Kidney Disease: Improving Global Outcomes (KDIGO) recom-
mendations for patients with kidney failure [16]. Serum calcium
and albumin were in the normal range in each treatment group.
Approximately one-third of the patients were treated with a
calcium-based phosphate binder and half were treated with the
non-calcium-based phosphate binder, sevelamer; 7% were
Table 2. Summary of reasons for screening failure
Reason patient did not meet entry criteria All screened (N¼ 645)
Inclusion criteria 239
Exclusion criteria 30
Both inclusion and exclusion 1
Withdrew consent 42
Lost to follow-up 0
Other 59
CT not completed/not evaluable 19
Kidney transplant 2
Screening/enrolment closed 32
Other (reason not specified) 6
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treated with lanthanum and 12% with another non-calcium-
based phosphate binder (Table 5). Statins were used by 62% of
patients, calcimimetics by 28%, warfarin by 7% and activated vi-
tamin D by 53%. More patients with the highest Agatston CAC
scores at baseline (>1000 U) were being treated with non-
calcium-based phosphate binders, calcimimetics, statins or
warfarin, whereas patients with lower Agatston CAC scores
were more likely to be treated with calcium-based binders.
Measures of cardiovascular calcification
Baseline calcium scores (Agatston and volume) for coronary ar-
tery, aorta and aortic valve were not normally distributed. Thus
summary statistics at each location are presented as medians
(25th–75th percentile) and geometric means (95% confidence in-
terval). Median Agatston scores and calcium volume scores, re-
spectively, were 730 U and 666 for the coronary arteries, 1728 U
and 1418 for the aorta and 103 U and 107 for the aortic valve
(Table 6 and Figure 2). For all patients combined, the correlation
at baseline between Agatston CAC scores and CAC calcium vol-
ume scores was 0.968 (P< 0.001). As expected, median Agatston
scores and calcium volume scores in the aorta and the aortic
valve were numerically higher in patients with a baseline
Agatston CAC score >1000 U than in those with a baseline score
of 100–399 U. Among the 115 patients with an Agatston CAC
score >1000 U at baseline, the score at the aorta and aortic arch
was >100 U for 110 (96%) and 44 (38%) patients, respectively.
Table 3. Demographic and baseline characteristics
Coronary artery calcium score (Agatston) category
Characteristic
100–399 U 400–1000 U >1000 U Total
(n¼ 82) (n¼ 77) (n¼ 115) (N¼ 274)
Age (years), mean 6 SD 61.0 6 9.1 62.9 6 8.7 65.9 6 8.3 63.6 6 8.9
Sex, n (%)
Male 51 (62) 42 (55) 74 (64) 167 (61)
Female 31 (38) 35 (45) 41 (36) 107 (39)
Race, n (%)
White 54 (66) 50 (65) 84 (73) 188 (69)
Black or African American 21 (26) 19 (25) 21 (18) 61 (22)
Asian 4 (5) 4 (5) 2 (2) 10 (4)
Other 0 0 4 (4) 4 (1)
Not reported 3 (4) 4 (5) 5 (4) 12 (4)
Ethnicity, n (%)
Hispanic or Latino 31 (38) 29 (38) 40 (35) 100 (36)
Body mass index (kg/m2) 28.4 6 6.7 29.6 6 6.2 29.0 6 5.6 29.0 6 6.1
Vital signs, mean 6 SD
Systolic blood pressure (mmHg) 138.8 6 21.5 136.1 6 25.6 136.4 6 26.6 137.0 6 24.9
Diastolic blood pressure (mmHg) 72.3 6 11.6 70.1 6 13.6 65.5 6 13.6 68.8 6 13.3
Medical history, n (%)
Diabetes mellitus 48 (59) 47 (61) 75 (65) 170 (62)
Hypertension 77 (94) 71 (92) 107 (93) 255 (93)
Peripheral vascular disease 13 (16) 9 (12) 14 (12) 36 (13)
Cerebrovascular accident 11 (13) 6 (8) 15 (13) 32 (12)
Myocardial infarction 9 (11) 6 (8) 16 (14) 31 (11)
Coronary artery disease 12 (15) 15 (19) 34 (30) 61 (22)
Congestive heart failure 10 (12) 12 (16) 21 (18) 43 (16)
Time on haemodialysis (months)
Median (25th–75th percentile) 37.9 (19.1–66.1) 44.3 (19.5–77.0) 43.4 (20.4–74.8) 42.4 (19.5–74.8)
<12 months, n (%) 9 (11) 7 (9) 15 (13) 31 (11)
12–36 months, n (%) 31 (38) 26 (34) 36 (31) 93 (34)
>36 months, n (%) 42 (51) 44 (57) 64 (56) 150 (55)
Table 4. Baseline mineral metabolism parameters
Coronary artery calcium score (Agatston) category
Baseline laboratory parameter
100–399 U 400–1000 U >1000 U Total
(N¼ 82) (n¼ 77) (n¼ 115) (N¼ 274)
Parathyroid hormone (pg/mL), median (25th–75th percentile) 312 (240–482) 318 (213–501) 362 (238–587) 335 (231–530)
Magnesium (mg/dL), mean 6 SD 2.5 6 0.4 2.5 6 0.4 2.4 6 0.4 2.5 6 0.4
Albumin (g/dL), mean 6 SD 4.0 6 0.3 4.0 6 0.3 3.9 6 0.3 4.0 6 0.3
Uncorrected serum calcium (mg/dL), mean 6 SD 8.7 6 0.8 9.0 6 0.8 8.9 6 0.6 8.8 6 0.7
Corrected serum calciuma (mg/dL), mean 6 SD 8.7 6 0.7 9.0 6 0.7 8.9 6 0.7 8.9 6 0.7
Alkaline phosphatase (U/L), mean 6 SD 110.8 6 48.7 112.6 6 62.0 118.6 6 81.8 114.7 6 68.1
aCorrected serum calcium¼uncorrected serum calciumþ0.8 (4 serum albumin).
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Table 5. Baseline medication use
Coronary artery calcium score (Agatston) category
Baseline medication
100–399 U 400–1000 U >1000 U Total
(n¼ 82) (n¼ 77) (n¼ 115) (N¼ 274)
Calcium-based phosphate binders, n (%) 27 (33) 20 (26) 35 (30) 82 (30)
Non-calcium-based phosphate binders, n (%)
Sevelamer 37 (45) 39 (51) 61 (53) 137 (50)
Lanthanum 4 (5) 3 (4) 12 (10) 19 (7)
Other 10 (12) 6 (8) 18 (16) 34 (12)
Calcimimetics, n (%) 20 (24) 21 (27) 37 (32) 78 (28)
Statins, n (%) 47 (57) 44 (57) 78 (68) 169 (62)
Warfarin, n (%) 3 (4) 3 (4) 12 (10) 18 (7)
Activated vitamin D, n (%) 47 (57) 39 (51) 58 (50) 144 (53)
Table 6. Baseline calcification assessments using Agatston and volume methods












100–399 U (n¼82) 210 (149–285) 207 6 9 204 (163–278) 212 6 11
400–1000 U (n¼ 77) 598 (479–757) 602 6 19 596 (441–692) 564 6 17
>1000 U (n¼115) 1617 (1222–1903) 1600 6 52 1378 (1068–1640) 1324 6 44
Total (n¼ 274) 730 (315–1435) 659 6 45 666 (310–1234) 602 6 37
Aorta
100–399 U (n¼77) 984 (427–2429) 926 6 465 807 (344–2096) 830 6 368
400–1000 U (n¼ 72) 1446 (411–3904) 1102 6 570 1217 (360–3040) 969 6 440
>1000 U (n¼113) 3620 (1305–7302) 2617 6 785 2837 (1099–6063) 2219 6 605
Total (n¼ 262) 1728 (625–4978) 1520 6 407 1418 (536–4052) 1323 6 315
Aortic valve
100–399 U (n¼42) 73 (31–192) 60 6 31 55 (37–209) 69 6 27
400–1000 U (n¼ 41) 76 (31–231) 89 6 46 86 (46–219) 92 6 37
>1000 U (n¼74) 137 (32–395) 102 6 73 136 (37–353) 113 6 57
Total (n¼ 157) 103 (31–262) 85 6 38 107 (38–278) 94 6 30
SE, standard error.
FIGURE 2: Distribution of baseline coronary artery calcium scores (Agatston and calcium volume).
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Factors associated with CAC score at baseline
In the multivariable-adjusted linear regression analysis that re-
quired a 0.10 significance level for variables to remain in the
model, older age (P< 0.001) and diabetes mellitus (P¼ 0.022)
were independently associated with higher baseline CAC
volume scores (Table 7).
DISCUSSION
Cardiovascular calcification is highly prevalent in patients with
impaired kidney function; at least 80% of patients receiving
maintenance haemodialysis exhibit some degree of cardiovas-
cular calcification [14, 27]. Cardiovascular calcification is also
associated with adverse outcomes [28–31]. Among 181 consecu-
tive patients with non-dialysis-requiring CKD, baseline CAC
score and CAC score progression predicted the occurrence of
cardiac death and/or myocardial infarction [32]. Numerous
observations support the contribution of valvular and vascular
calcification to morbidity and mortality in CKD [33]. CAC has
been associated with increased arterial stiffness [34, 35], left
ventricular hypertrophy [36], epicardial adipose tissue thickness
and volume, myocardial ischaemia [37] and pro-arrhythmic
electrocardiographic abnormalities [35]. Valvular calcification
causes restriction of leaflet motion [38, 39], increased transval-
vular gradient [38, 39] and left atrium enlargement [38, 39] and
is associated with reduced survival [40].
In this study, patients with higher Agatston CAC scores at
baseline were more likely to be treated with a non-calcium-
based phosphate binder, calcimimetics, statin or warfarin.
These management strategies were consistent with recent
KDIGO CKD-MBD guidelines [16]. Intense research has been un-
dertaken in recent years to identify modifiable risk factors that
induce calcification, as well as drugs that may reduce its pro-
gression, in the hope of reducing the incidence of cardiovascu-
lar events and mortality in patients with impaired kidney
function [16]. Multiple prior studies have tested the effects of a
variety of interventions that modify mineral metabolism on cal-
cification of the coronary arteries, aorta and cardiac valves.
Treatment with non-calcium-based phosphate binders has
been shown to attenuate CAC progression compared with
calcium-based phosphate binders [41]. Similarly, in a random-
ized clinical trial (ADVANCE), cinacalcet was compared with
placebo on top of standard care including calcitriol or vitamin D
analogues in patients receiving haemodialysis with moderate-
to-severe secondary hyperparathyroidism. Cinacalcet was asso-
ciated with slower progression of calcification from baseline to
Week 52 in the thoracic aorta (cinacalcet 19%, control 33%;
P¼ 0.055), aortic valve (cinacalcet 6%, control 52%; P¼ 0.014) and
mitral valve (cinacalcet 12%, control 54%; P¼ 0.053), but the trial
did not meet its primary endpoint for mean change in Agatston
CAC score (cinacalcet 24%, control 31%; P¼ 0.073) [26]. EVOLVE,
a large event-driven randomized clinical trial comparing
cinacalcet with placebo on top of standard care, showed gener-
ally favourable effects on cardiovascular events and fracture,
but the primary endpoint was also not met [42].
The pathogenesis of cardiovascular calcification in CKD is
complex and only partly understood [10]. Irrespective of the
triggering factors, calcium–phosphate crystals may deposit in
the soft tissues if there is an imbalance of calcification inhibi-
tors and promoters [43]. In the presence of both high and low
mineral turnover, it has been postulated that bone cannot
accommodate additional calcium and phosphate in the matrix,
leading to excess circulating ions and eventually precipitation
of these minerals in soft tissue [44]. Cardiovascular calcification
has often been described as a passive degenerative process due
to ‘wear and tear’ and progressive senescence [5, 45]. However,
active cellular mechanisms are principally responsible for ec-
topic calcification [6, 10, 45]. Laboratory experiments show that
excess calcium and/or phosphate, along with decreased levels
of calcification inhibitors, induce vascular smooth muscle cells
to differentiate and assume an osteoblastic phenotype. These
cells initiate deposition of collagen, which becomes calcified in
the arterial wall [43]. Micronutrients such as magnesium and
phosphorus may have a similar role in valvular calcification
[45]. Further stimulus towards the accumulation of soft tissue
calcification in uraemia is provided by the frequent depletion of
inhibitors of calcification [46]. For example, low levels of fetuin-A,
osteoprotegerin, MGP, vitamin K and pyrophosphate have been
consistently described in patients with CKD and associated with
vascular calcification [10].
To date, there are no approved therapies to directly slow the
progression of cardiovascular calcification. Although a number
of therapies potentially target the calcification process, such as
pyrophosphate, bisphosphonates, thiosulphate and vitamin K,
none of these compounds have been shown to be effective in or
approved for the treatment or prevention of cardiovascular
calcification. Current guidelines consider patients with CKD and
cardiovascular calcification to be at the highest cardiovascular
risk and suggest managing the biochemical abnormalities
observed in patients with CKD as a therapeutic strategy to
mitigate progression of cardiovascular calcification [16].
Preclinical data showed that SNF472 reduced development
of cardiovascular calcification by up to 80% [47]. In early clinical
trials, SNF472 was well tolerated in humans [48, 49]. The
CaLIPSO study was designed to test the hypothesis that SNF472
slows the progression of calcification in the coronary arteries,
aorta and aortic valve. CaLIPSO was powered to detect a clini-
cally meaningful reduction in CAC as measured by CAC volume
scores between the combined SNF472 dose groups versus pla-
cebo after 52 weeks of treatment.
The CaLIPSO study has limitations. This Phase 2 trial was
not powered to evaluate a reduction in cardiovascular mortality
and morbidity. Future appropriately powered studies will be
needed to assess the effects of SNF472 on cardiovascular
Table 7. Linear regression analysis of predictors of log-transformed coronary artery calcium volume scores at baseline
Variable Parameter estimate Standard error P-value Model R2
Intercept 4.875 0.409 <0.001 –
Age (years) 0.022 0.006 <0.001 0.039
Coexistent diabetes 0.255 0.111 0.022 0.060
Candidate variables in the initial model were sex (male/female), age (years), dialysis vintage (months), PTH, magnesium, diabetes (yes/no), non-calcium-based phos-
phate binder use (yes/no), statin use (yes/no), warfarin use (yes/no) and history of overt atherosclerotic cardiovascular disease (yes/no). Stepwise regression was used
to identify factors associated with baseline log-transformed CAC volume score with 0.10 significance level for entry into the model and 0.10 significance level for
remaining in the model.
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outcomes. The relatively short follow-up (52 weeks) and the use
of different CT scanners at study sites are other potential limita-
tions. To increase the quality and comparability of evaluations,
a common procedure for CT scanning acquisition was used and
CT scans were evaluated in a central core laboratory by readers
blinded to treatment assignment using common methods for
calcium quantitation in the coronary arteries, including
Agatston and volume scores. Although multiple factors may af-
fect the progression of cardiovascular calcification, patients
recruited in the CaLIPSO study were only stratified according to
baseline Agatston CAC score, a powerful predictor of CAC pro-
gression. Serum phosphate, which was collected in a subset of
patients, was not available for this analysis. Data on dialysis
session duration and dialysate calcium concentration were not
collected.
In summary, the CaLIPSO trial was designed to investigate
the inhibitory effect of SNF472 on the progression of cardiovas-
cular calcification in patients on maintenance haemodialysis.
The results will determine further evaluation of SNF472 in man-
aging cardiovascular disease in this patient population.
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